SPECROPHOTOMETRIC ESTIMATION AND STATISTICAL CORRELATION FOR ROSIGLITAZONE IN RAT AND HUMAN PLASMA

  • Lopamudra Adhikari
  • Uma Shankar Mishra
  • P.N Murthy

Abstract

ABSTRACT

 

Objective: A rapid and sensitive Spectrophotometric method was developed for Rosiglitazone in rat and human plasma.

Method: The sample was prepared by simple extraction method without derivatization and no use of buffer .Methanol and acetonitrile were used as the solvents in the proposed methods.

Results: Calibration range extended for rosiglitazone from1mcg/ml to 10 mcg/ml in rat plasma and 1mcg/ml to 17mcg/ml in human plasma with good regression coefficients in both the cases. The Limit of Detection and Limit of Quantification were found out to be 0.726mcg/ml and 2.2mcg/ml in rat plasma and 0.414mcg/ml and 1.255mcg/ml in human plasma. Assay results from the proposed method were found to be 100.2% and 100.12% in rat and human plasma respectively. Stability of the drug in both the plasma was found to be suitable in both refrigerated and ambient conditions.

Conclusion: The current method implied no significance difference as for estimation in rat and human plasma as tested from ANOVA analysis and can be extended pharmacokinetic studies. The proposed method was found prudent to be used in routine QC analysis.

Keywords: Rosiglitazone, UV-Vis Spectrophotometer, Rat Plasma, Human Plasma, Statistical Correlation

References

1. G. Valsamakis and S. Kumar. Insulin action enhancers for the management of Type 2 diabetes mellitus. Expert Opin. Pharmacother.7(1): 1413–1421 (2000).
2. C.L. Wu, L.H. Lee, B.R. Lee, and C.-J. Lee. Biotechnology-Derived Pharmaceuticals. Clin. Trials Drugs Biopharm. 363–372 (2006).
3. A.Y. Cheng and I.G. Fantus.Oral antihyperglycemic therapy for type 2 diabetes mellitus. CMAJ. 172(2): 213–226 (2005).
4. L.S. Phillips, G. Grunberger, E. Miller, R. Patwardhan, E.B.Rappaport, and A. Salzman. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes.Rosiglitazone Clinical Trials Study Group. Diab. Care. 24(2):308–315 (2001).
5. S.J. Baldwin, S.E. Clarke, and R.J. Chenery. haracterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone. Br. J. Clin. Pharmacol. 48: 424–432 (1999).
6. Balfour JA, Plosker GL: Rosiglitazone. Drugs 1999, 57(6):921-30.
7. A.Y.Y. Cheng, I.G. Fantus, CMAJ 172 (2005) 213.
8. L.S. Phillips, G. Grunberger, E. Miller, R. Patwardhan, E.B. Rappaport, A. Salzman,Rosiglitazone Clinical Trials Study Group, Diab. Care 24 (2001) 308.
9. Validation of Analytical Procedures,Proceedings of International Conference on Harmonisation(ICH).Commission of European Communities,1996.
Statistics
146 Views | 267 Downloads
How to Cite
Adhikari, L., U. S. Mishra, and P. Murthy. “SPECROPHOTOMETRIC ESTIMATION AND STATISTICAL CORRELATION FOR ROSIGLITAZONE IN RAT AND HUMAN PLASMA”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 6, no. 7, Aug. 2013, pp. 138-41, https://innovareacademics.in/journals/index.php/ajpcr/article/view/299.
Section
Articles